See more : Electro Aço Altona S.A. (EALT4.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Nexalin Technology, Inc. (NXL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nexalin Technology, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Life Healthcare Group Holdings Limited (LTGHF) Income Statement Analysis – Financial Results
- Trifecta Gold Ltd. (TRRFF) Income Statement Analysis – Financial Results
- Telecom Service One Holdings Limited (3997.HK) Income Statement Analysis – Financial Results
- Svaraj Trading and Agencies Limited (ZSVARAJT.BO) Income Statement Analysis – Financial Results
- Sonasoft Corporation (SSFT) Income Statement Analysis – Financial Results
Nexalin Technology, Inc. (NXL)
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 110.75K | 1.32M | 144.07K | 242.91K | 207.38K |
| Cost of Revenue | 25.69K | 363.21K | 21.44K | 29.04K | 218.21K |
| Gross Profit | 85.06K | 958.15K | 122.62K | 213.88K | -10.83K |
| Gross Profit Ratio | 76.80% | 72.51% | 85.12% | 88.05% | -5.22% |
| Research & Development | 1.92M | 511.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 5.78M | 2.79M | 6.14M | 3.47M | 78.13K |
| Selling & Marketing | 0.00 | 886.41K | 35.49K | 10.71K | 1.38M |
| SG&A | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Other Expenses | 0.00 | 171.68K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Cost & Expenses | 5.81M | 3.15M | 6.16M | 3.50M | 1.67M |
| Interest Income | 0.00 | 59.38K | 82.32K | 78.68K | 80.99K |
| Interest Expense | 38.84K | 59.38K | 82.32K | 78.68K | 80.99K |
| Depreciation & Amortization | 4.25K | 5.72K | 537.00 | 429.00 | 535.00 |
| EBITDA | -5.69M | -1.83M | -6.00M | -3.32M | -1.47M |
| EBITDA Ratio | -5,139.63% | -125.69% | -4,177.33% | -1,341.21% | -706.72% |
| Operating Income | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Operating Income Ratio | -5,143.48% | -138.72% | -4,177.70% | -1,341.38% | -706.98% |
| Total Other Income/Expenses | 1.05M | 135.22K | -59.40K | -145.08K | -3.56M |
| Income Before Tax | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Income Before Tax Ratio | -4,197.56% | -128.49% | -4,218.93% | -1,401.11% | -2,421.22% |
| Income Tax Expense | 0.00 | 228.00K | 82.32K | 78.68K | 5.00 |
| Net Income | -4.65M | -1.93M | -6.16M | -3.48M | -5.02M |
| Net Income Ratio | -4,197.56% | -145.75% | -4,276.07% | -1,433.50% | -2,421.22% |
| EPS | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| EPS Diluted | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
| Weighted Avg Shares Out (Dil) | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and LOBO EV Technologies Ltd. (Nasdaq:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this...
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
‘Breaking Barriers' Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting HOUSTON, TX, July 18, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced...
Nexalin Technology Announces Closing of $5.2 Million Public Offering
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross...
The 3 Smartest Penny Stocks to Buy With Your Money Right Now
Penny stocks are risky and are known for crashing and burning fast. Most of these stocks are unstable and attract a lot of speculations and shifts in the market.
Why Is Nexalin Technology (NXL) Stock Down 35% Today?
Nexalin Technology (NASDAQ: NXL ) stock is down on Friday after the medical device company priced a public offering of its shares. Nexalin Technology is selling 3 million shares of NXL stock for $1.75 each in this public offering.
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before...
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia
HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company's non-invasive...
Why Is Nexalin Technology (NXL) Stock Down 29% Today?
Nexalin Technology (NASDAQ: NXL ) stock is retreating on Friday after the medical device company's shares underwent a massive rally late yesterday. That rally came alongside regulatory approval of one of Nexalin Technology's neurostimulation devices.
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024...
Source: https://incomestatements.info
Category: Stock Reports